According to a scientific research, the COVID-19 vaccine produced by the AstraZeneca and Pfizer-BioNTech alliance is still widely effective against the Delta and Kappa variants of the virus that causes COVID-19. According to a scientific research, these viruses have been used for the first time in India. It was discovered and supported to continue to promote injections.
According to a statement, the study by Oxford University researchers published in the journal Cell investigated the ability of antibodies in the blood of twice vaccinated people to neutralize highly infectious variants of Delta and Kappa.
“There is no evidence of widespread escape, indicating that the current generation of vaccines will provide protection against the B.1.617 lineage,” the paper said, using common codes to refer to Delta and Kappa variants.
However, they warned that the concentration of neutralizing antibodies in the blood has decreased, which may lead to some breakthrough infections.
Last week, an analysis by Public Health England (PHE) showed that vaccines produced by Pfizer and AstraZeneca provide more than 90% high protection against hospitalization due to Delta variants.
“We are very pleased to see that the non-clinical results and these data published by Oxford, as well as the recent early real-world analysis by the British Public Health Department, provide us with a positive sign that our vaccine can have a significant impact on the Delta variant. “AstraZeneca executive Mene Pangalos said in a separate statement.
The chief scientist of the World Health Organization said on Friday that the Delta variant is becoming the leading global version of the disease.
Researchers at the University of Oxford also analyzed the reinfection patterns of people who had previously had COVID-19. Among individuals previously infected with the Beta and Gamma lineages in South Africa and Brazil, respectively, the risk of reinfection with the Delta variant appears to be particularly high.
In contrast, the infection of Alpha or B117 variants, first discovered in the UK, confers “reasonable” cross-protection against all variants of interest, making it a template for shaping the next generation of vaccines.
The researchers said: “B117 may be a candidate for the new variant vaccine that offers the broadest protection.”